Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities

Area of Science:

• Oncology
• Molecular Biology
• Translational Science

Background:

• Lung cancer is a leading global cause of mortality, with non-small cell lung cancer (NSCLC) comprising over 80% of cases.
• Traditional treatments like chemotherapy and surgery have limited efficacy and patient survival rates.
• Advances in molecular biology reveal diverse driver gene mutations and intracellular pathways in lung carcinogenesis.

Purpose of the Study:

• To provide a comprehensive update on targeted therapies for driver mutations in NSCLC.
• To discuss challenges associated with acquired drug resistance in targeted lung cancer therapy.
• To explore emerging treatment modalities for lung cancer.

Main Methods:

• Review of current literature on targeted therapies for NSCLC.
• Analysis of molecular subgroups and their associated driver mutations.
• Examination of mechanisms of acquired drug resistance.
• Identification of novel therapeutic strategies.

Main Results:

• Targeted therapies offer improved efficacy and reduced toxicity compared to systemic treatments by targeting tumor-specific molecules.
• Driver mutations in NSCLC present distinct molecular subgroups amenable to targeted agent development.
• Acquired drug resistance remains a significant challenge, necessitating further research into overcoming treatment limitations.

Conclusions:

• Targeted therapies represent a significant advancement in NSCLC treatment, offering personalized approaches based on molecular profiling.
• Addressing acquired drug resistance is crucial for improving long-term patient outcomes.
• Continued research into novel targeted agents and combination therapies holds promise for future lung cancer management.